{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:47:40Z","timestamp":1773661660714,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["EEQ\/2017\/000239"],"award-info":[{"award-number":["EEQ\/2017\/000239"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["F.4\u20137\/2015\/DRS-III"],"award-info":[{"award-number":["F.4\u20137\/2015\/DRS-III"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022012","name":"CSIR - Institute of Microbial Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemistry and Physics of Lipids"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.chemphyslip.2022.105207","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T11:04:20Z","timestamp":1653390260000},"page":"105207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of liver specific ionizable lipid nanocarrier in the delivery of siRNA"],"prefix":"10.1016","volume":"246","author":[{"given":"Shilpa","family":"Rana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.chemphyslip.2022.105207_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","article-title":"Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria","volume":"60","author":"Badri","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jconrel.2011.10.009","article-title":"Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design","volume":"158","author":"Buyens","year":"2012","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib4","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1016\/j.biomaterials.2012.03.038","article-title":"Endosomal escape and transfection efficiency of PEGylated cationic liposome-DNA complexes prepared with an acid-labile PEG-lipid","volume":"33","author":"Chan","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib6","doi-asserted-by":"crossref","first-page":"e61050","DOI":"10.1371\/journal.pone.0061050","article-title":"Role of hepcidin in the setting of hypoferremia during acute inflammation.","volume":"8(4)","author":"Deschemin","year":"2013","journal-title":"PLOS one"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting \u2014 Strategies and applications","volume":"203","author":"D\u2019Souza","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2012.075515","article-title":"Iron refractory iron deficiency anemia","volume":"98","author":"De Falco","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib9","doi-asserted-by":"crossref","first-page":"1700375","DOI":"10.1002\/smtd.201700375","article-title":"State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery.","volume":"2","author":"Evers","year":"2018","journal-title":"Small Methods"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib10","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3389\/fphar.2020.598175","article-title":"Rationale and application of PEGylated lipid-based system for advanced target delivery of siRNA","volume":"11","author":"Ge","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib11","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1158\/1538-7445.AM2014-3847","article-title":"Abstract 3847: The anti-hepcidin Spiegelmer\u00ae Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study","volume":"74","author":"Georgiev","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-Dose Pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib15","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.omtn.2018.02.005","article-title":"Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in vivo","volume":"11","author":"Javanbakht","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib19","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.2147\/IJN.S202424","article-title":"Dimeric c (RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer.","volume":"14","author":"Kebebe","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib20","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib21","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib24","doi-asserted-by":"crossref","first-page":"eabd6889","DOI":"10.1126\/sciadv.abd6889","article-title":"BBB pathophysiology\u2013independent delivery of siRNA in traumatic brain injury","volume":"7","author":"Li","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method.","volume":"25(4)","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib26","first-page":"13","article-title":"The role of water in protein\u2019s behavior: the two dynamical crossovers studied by NMR and FTIR techniques","author":"Mallamace","year":"2014","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.colsurfa.2011.07.032","article-title":"Evaluation of dialysis membrane process for quantifying the in vitro drug-release from colloidal drug carriers","volume":"389","author":"Moreno-Bautista","year":"2011","journal-title":"Colloids Surf. A-Physicochem. Eng. Asp. - COLLOID Surf. A"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib28","first-page":"1","article-title":"Effect of gal\/GalNAc regioisomerism in galactosylated liposomes on asialoglycoprotein receptor-mediated hepatocyte-selective targeting in vivo","author":"Nie","year":"2019","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2020.102239","article-title":"siRNA based drug design, quality, delivery and clinical translation","volume":"29","author":"Subhan","year":"2020","journal-title":"Nanomed.: Nanotechnol., Biol. Med."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/nat.2019.0796","article-title":"Nonclinical safety profile of revusiran, a 1st-generation GalNAc-siRNA conjugate for treatment of hereditary transthyretin-mediated amyloidosis","volume":"30","author":"Sutherland","year":"2020","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.addr.2009.03.003","article-title":"Lipid-based systemic delivery of siRNA","volume":"61","author":"Tseng","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2015.11.056","article-title":"Effect of surface properties on liposomal siRNA delivery","volume":"79","author":"Xia","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.chemphyslip.2022.105207_bib41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.chemphyslip.2022.105207_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Chemistry and Physics of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009308422000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009308422000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:58:44Z","timestamp":1762113524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009308422000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":42,"alternative-id":["S0009308422000354"],"URL":"https:\/\/doi.org\/10.1016\/j.chemphyslip.2022.105207","relation":{},"ISSN":["0009-3084"],"issn-type":[{"value":"0009-3084","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of liver specific ionizable lipid nanocarrier in the delivery of siRNA","name":"articletitle","label":"Article Title"},{"value":"Chemistry and Physics of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chemphyslip.2022.105207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105207"}}